Camptothecin inhibits the progression of nasopharyngeal carcinoma by inhibiting transforming growth factor-beta (TGF-β), PI3K, and PKB expression, but the overexpression of TGF-β mitigates this effect [53]. Here, PIK3CG is linked to nasopharyngeal carcinoma.